• Context Therapeutics amended its exclusive CT-202 license with BioAtla to eliminate all future milestone and royalty obligations in exchange for a fully paid-up, non-terminable license.
• The amendment requires a USD 4.5 million upfront payment, with a final USD 2 million payment due by Aug. 1, 2026.
• Phase 1 initiation for the CT-202 trial is expected in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-035793), on May 18, 2026, and is solely responsible for the information contained therein.